Systemic treatment with CAR-engineered T cells against PSCA delays subcutaneous tumor growth and prolongs survival of mice

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Hillerdal, Victoria ^a   Ramachandran, Mohanraj ^a   Leja, Justyna ^a   Essand, Magnus ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

Adoptive transfer; CAR T cells; Genetic engineering; Prostate cancer; PSCA

Indexed keywords

CHIMERIC ANTIGEN RECEPTOR; GAMMA INTERFERON; INTERLEUKIN 2; LYMPHOCYTE ANTIGEN RECEPTOR; PROSTATE STEM CELL ANTIGEN; UNCLASSIFIED DRUG;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CELL KILLING; CONTROLLED STUDY; CYTOKINE RELEASE; GENETIC ENGINEERING; HUMAN; HUMAN CELL; IN VITRO STUDY; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; SKIN TUMOR; SUBCUTANEOUS TUMOR; SURVIVAL; T LYMPHOCYTE; TREATMENT OUTCOME;

ANIMALS; ANTIGENS, NEOPLASM; CELL DEGRANULATION; CELL LINE, TUMOR; CELL PROLIFERATION; COCULTURE TECHNIQUES; CYTOKINES; CYTOTOXICITY, IMMUNOLOGIC; GENETIC THERAPY; GPI-LINKED PROTEINS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LYSOSOMAL-ASSOCIATED MEMBRANE PROTEIN 1; MALE; MICE; MICE, NUDE; NEOPLASM PROTEINS; PROSTATIC NEOPLASMS; RECEPTORS, ANTIGEN, T-CELL; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES; TIME FACTORS; TRANSDUCTION, GENETIC; TRANSFECTION; TUMOR BURDEN;

EID: 84892447898     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-30     Document Type: Article

References (30)

1. Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer 2008, 8(4):299-308. 10.1038/nrc2355, 2553205, 18354418.
2. Essand M, Loskog AS. Genetically engineered T cells for the treatment of cancer. J Intern Med 2013, 273(2):166-181. 10.1111/joim.12020, 3607417, 23198862.
3. Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM, Royal RE, Topalian SL, Kammula US, Restifo NP, Zheng Z, Nahvi A, de Vries CR, Rogers-Freezer LJ, Mavroukakis SA, Rosenberg SA. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006, 314(5796):126-129. 10.1126/science.1129003, 2267026, 16946036.
4. Sadelain M, Brentjens R, Riviere I. The promise and potential pitfalls of chimeric antigen receptors. Curr Opin Immunol 2009, 21(2):215-223. 10.1016/j.coi.2009.02.009, 19327974.
5. Kowolik CM, Topp MS, Gonzalez S, Pfeiffer T, Olivares S, Gonzalez N, Smith DD, Forman SJ, Jensen MC, Cooper LJN. CD28 Costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells. Cancer Res 2006, 66(22):10995-11004. 10.1158/0008-5472.CAN-06-0160, 17108138.
6. Song D-G, Ye Q, Carpenito C, Poussin M, Wang L-P, Ji C, Figini M, June CH, Coukos G, Powell DJ. In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB). Cancer Res 2011, 71(13):4617-4627. 10.1158/0008-5472.CAN-11-0422, 21546571.
7. Pule MA, Straathof KC, Dotti G, Heslop HE, Rooney CM, Brenner MK. A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells. Mol Ther 2005, 12(5):933-941. 10.1016/j.ymthe.2005.04.016, 15979412.
8. Song DG, Ye Q, Poussin M, Harms GM, Figini M, Powell DJ. CD27 costimulation augments the survival and antitumor activity of redirected human T cells in vivo. Blood 2012, 119(3):696-706. 10.1182/blood-2011-03-344275, 22117050.
9. Wang J, Jensen M, Lin Y, Sui X, Chen E, Lindgren CG, Till B, Raubitschek A, Forman SJ, Qian X, James S, Greenberg P, Riddell S, Press OW. Optimizing adoptive polyclonal T cell immunotherapy of lymphomas, using a chimeric T cell receptor possessing CD28 and CD137 costimulatory domains. Hum Gene Ther 2007, 18(8):712-725. 10.1089/hum.2007.028, 17685852.
10. Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A, June CH. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 2011, 3(95):95ra73. 3393096, 21832238.
11. Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR, Teachey DT, Chew A, Hauck B, Wright JF, Milone MC, Levine BL, June CH. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. The New England J of Med 2013, 368(16):1509-1518.
12. Gu Z, Thomas G, Yamashiro J, Shintaku IP, Dorey F, Raitano A, Witte ON, Said JW, Loda M, Reiter RE. Prostate stem cell antigen (PSCA) expression increases with high gleason score, advanced stage and bone metastasis in prostate cancer. Oncogene 2000, 19(10):1288-1296. 10.1038/sj.onc.1203426, 10713670.
13. Zhang KQ, Yang F, Ye J, Jiang M, Liu Y, Jin FS, Wu YZ. A novel DNA/peptide combined vaccine induces PSCA-specific cytotoxic T-lymphocyte responses and suppresses tumor growth in experimental prostate cancer. Urology 2012, 79(6):1410 e1417-1413.
14. Kiessling A, Schmitz M, Stevanovic S, Weigle B, Holig K, Fussel M, Fussel S, Meye A, Wirth MP, Rieber EP. Prostate stem cell antigen: identification of immunogenic peptides and assessment of reactive CD8+ T cells in prostate cancer patients. Int J Cancer 2002, 102(4):390-397. 10.1002/ijc.10713, 12402309.
15. Forsberg O, Carlsson B, Malmstrom PU, Ullenhag G, Totterman TH, Essand M. High frequency of prostate antigen-directed T cells in cancer patients compared to healthy age-matched individuals. Prostate 2009, 69(1):70-81. 10.1002/pros.20858, 18814178.
16. Leyton JV, Olafsen T, Lepin EJ, Hahm S, Bauer KB, Reiter RE, Wu AM. Humanized radioiodinated minibody for imaging of prostate stem cell antigen-expressing tumors. Clin Cancer Res 2008, 14(22):7488-7496. 10.1158/1078-0432.CCR-07-5093, 2720761, 19010866.
17. Antonarakis E, Carducci M, Eisenberger M, Denmeade S, Slovin S, Jelaca-Maxwell K, Vincent M, Scher H, Morris M. Phase I rapid dose-escalation study of AGS-1C4D4, a human anti-PSCA (prostate stem cell antigen) monoclonal antibody, in patients with castration-resistant prostate cancer: a PCCTC trial. Cancer Chemother Pharmacol 2012, 69(3):763-771. 10.1007/s00280-011-1759-9, 3586214, 22020316.
18. Morris MJ, Eisenberger MA, Pili R, Denmeade SR, Rathkopf D, Slovin SF, Farrelly J, Chudow JJ, Vincent M, Scher HI, Carducci MA. A phase I/IIA study of AGS-PSCA for castration-resistant prostate cancer. Ann Oncol 2012, 23(10):2714-2719. 10.1093/annonc/mds078, 3457748, 22553195.
19. Olafsen T, Gu Z, Sherman MA, Leyton JV, Witkosky ME, Shively JE, Raubitschek AA, Morrison SL, Wu AM, Reiter RE. Targeting, imaging, and therapy using a humanized antiprostate stem cell antigen (PSCA) antibody. J Immunother 2007, 30(4):396-405. 10.1097/CJI.0b013e318031b53b, 17457214.
20. Yvon E, Del Vecchio M, Savoldo B, Hoyos V, Dutour A, Anichini A, Dotti G, Brenner MK. Immunotherapy of metastatic melanoma using genetically engineered GD2-specific T cells. Clin Cancer Res 2009, 15(18):5852-5860. 10.1158/1078-0432.CCR-08-3163, 2745508, 19737958.
21. Zheng Z, Chinnasamy N, Morgan RA. Protein L: a novel reagent for the detection of chimeric antigen receptor (CAR) expression by flow cytometry. J Transl Med 2012, 10:29. 10.1186/1479-5876-10-29, 3299624, 22330761.
22. Taylor RM, Severns V, Brown DC, Bisoffi M, Sillerud LO. Prostate cancer targeting motifs: expression of alphanu beta3, neurotensin receptor 1, prostate specific membrane antigen, and prostate stem cell antigen in human prostate cancer cell lines and xenografts. Prostate 2012, 72(5):523-532. 10.1002/pros.21454, 21748756.
23. Katari UL, Keirnan JM, Worth AC, Hodges SE, Leen AM, Fisher WE, Vera JF. Engineered T cells for pancreatic cancer treatment. HPB: the Off J of the Int Hepato Pancreato Biliary Assoc 2011, 13(9):643-650.
24. Jalkut MW, Reiter RE. Role of prostate stem cell antigen in prostate cancer research. Curr Opin Urol 2002, 12(5):401-406. 10.1097/00042307-200209000-00006, 12172427.
25. Morgenroth A, Cartellieri M, Schmitz M, Gunes S, Weigle B, Bachmann M, Abken H, Rieber EP, Temme A. Targeting of tumor cells expressing the prostate stem cell antigen (PSCA) using genetically engineered T-cells. Prostate 2007, 67(10):1121-1131. 10.1002/pros.20608, 17492652.
26. Kloss CC, Condomines M, Cartellieri M, Bachmann M, Sadelain M. Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells. Nat Biotechnol 2013, 31(1):71-75.
27. Kochenderfer JN, Yu ZY, Frasheri D, Restifo NP, Rosenberg SA. Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells. Blood 2010, 116(19):3875-3886. 10.1182/blood-2010-01-265041, 2981541, 20631379.
28. Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan GQ, Citrin DE, Restifo NP, Robbins PF, Wunderlich JR, Morton KE, Laurencot CM, Steinberg SM, White DE, Dudley ME. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res 2011, 17(13):4550-4557. 10.1158/1078-0432.CCR-11-0116, 3131487, 21498393.
29. Besser MJ, Shapira-Frommer R, Treves AJ, Zippel D, Itzhaki O, Schallmach E, Kubi A, Shalmon B, Hardan I, Catane R, Segal E, Markel G, Apter S, Nun AB, Kuchuk I, Shimoni A, Nagler A, Schachter J. Minimally cultured or selected autologous tumor-infiltrating lymphocytes after a lympho-depleting chemotherapy regimen in metastatic melanoma patients. J Immunother 2009, 32(4):415-423. 10.1097/CJI.0b013e31819c8bda, 19342963.
30. Barach YS, Lee JS, Zang XX. T cell coinhibition in prostate cancer: new immune evasion pathways and emerging therapeutics. Trends Mol Med 2011, 17(1):47-55.